Kennedy Capital Management LLC Raises Position in Halozyme Therapeutics, Inc. $HALO

Kennedy Capital Management LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 433,766 shares of the biopharmaceutical company’s stock after buying an additional 50,209 shares during the period. Halozyme Therapeutics accounts for approximately 0.6% of Kennedy Capital Management LLC’s portfolio, making the stock its 17th largest holding. Kennedy Capital Management LLC’s holdings in Halozyme Therapeutics were worth $29,192,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Clark Capital Management Group Inc. increased its stake in Halozyme Therapeutics by 14.4% in the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after acquiring an additional 25,582 shares during the last quarter. Intech Investment Management LLC increased its stake in Halozyme Therapeutics by 46.0% in the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after acquiring an additional 46,850 shares during the last quarter. Allworth Financial LP increased its stake in Halozyme Therapeutics by 322.5% in the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after acquiring an additional 30,331 shares during the last quarter. Element Squared LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at $1,193,000. Finally, Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 3.2% in the third quarter. Dimensional Fund Advisors LP now owns 2,078,426 shares of the biopharmaceutical company’s stock valued at $152,431,000 after acquiring an additional 63,699 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 1.7%

Shares of NASDAQ:HALO opened at $69.50 on Friday. The stock’s 50-day moving average price is $67.51 and its 200-day moving average price is $68.76. Halozyme Therapeutics, Inc. has a 12-month low of $51.06 and a 12-month high of $82.22. The stock has a market capitalization of $8.24 billion, a P/E ratio of 25.00, a price-to-earnings-growth ratio of 0.29 and a beta of 0.88. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the firm earned $1.11 earnings per share. The company’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright raised their price objective on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the sale, the director directly owned 43,669 shares in the company, valued at $2,891,324.49. The trade was a 3.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 93,250 shares of company stock worth $6,299,746 over the last ninety days. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.